US Biotechnology: The Biotech Brief: Week of July 10, 2026

Research evidence excerpt

US Biotechnology: The Biotech Brief: Week of July 10, 2026

splant eligibility? Carefully selected patients with stage IV GLP-1: glucagon-like peptide -1

NSCLC may benefit from lung transplant, challenging traditional criteria (Bharat et al, IAS: International AIDS Society

JAMA). Not surprisingly, GLP-1 demand remains robust, with obesity coverage driving IgAN: immunoglobulin A nephropathy

strong uptake, reinforcing the category’s growth outlook (Shahzad et al, JAMA Health ISSCR: International Society for Stem Cell

Forum). Meanwhile, concerns are emerging FDA-approved Alzheimer’s blood tests may Research

generate more false positives than expected (Rubin, JAMA). In nephrology, phase 3 ISTH: International Society of Thrombosis and

ALIGN supports atrasentan’s benefit in IgAN, though proof of disease modification Hemostasis

remains unclear (Lee et al, Lancet). Finally, there are new calls as to whether routine

KOL: key opinion leader

isotretinoin lab monitoring is necessary (if you know, you know; Pierson et al, JAMA

Dermatol). For additional research you may have missed, see “Recent Research”. LBA: late-breaking abstract

NDA: new drug application

They did what!? nHCM: non-obstructive hypertrophic

While you’ve been eyeing the weekend, let’s rewind to what may have flown under the cardiomyopathy

radar. With Biopharma sentiment improving, we reviewed why the move could prove NMIBC: non-muscle invasive bladder cancer

durable (see our momentum note). We also published our July catalyst tracker

highlighting key watchpoints for 2H26 and early 2027 (see our July catalyst tracker). NSCLC: non-small cell lung cancer

Ahead of Biogen’s AD update at AAIC, we surveyed prescribers to gauge whether PDUFA: prescription drug user fee act